Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II (Q68368613)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

title

Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

author name string

H Saxenhofer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

P Weidmann

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

W F Riesen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

C Beretta-Piccoli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

C Fragiacomo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

R Wunderlin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

G Noseda

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

publication date

1 January 1990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Clinical Pharmacology

23 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

page(s)

101-105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

Regulation of HMG-CoA reductase

23 September 2019

cites work

1 reference

12 December 2020

Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test

1 reference

12 December 2020

Apolipoprotein E polymorphism and atherosclerosis

1 reference

12 December 2020

Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia

1 reference

12 December 2020

Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions.

1 reference

12 December 2020

Quantitation of apolipoprotein B by polyclonal and monoclonal antibodies

1 reference

12 December 2020

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

1 reference

12 December 2020

Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity

1 reference

12 December 2020

The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects

1 reference

12 December 2020

Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis

1 reference

12 December 2020

Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study

1 reference

12 December 2020

The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers

1 reference

12 December 2020

Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia

1 reference

12 December 2020

Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects

1 reference

12 December 2020

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

1 reference

12 December 2020

Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00280040

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2123791%20AND%20SRC:MED&resulttype=core&format=json

23 September 2019

1 reference